Chinese Expert Consensus 2025 on the Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction
10.3969/j.issn.1000-3614.2025.11.001
- VernacularTitle:射血分数保留的心力衰竭诊断与治疗中国专家共识2025
- Author:
Jingmin ZHOU
;
Jiefu YANG
- Collective Name:Chinese Expert Consensus Working Group on Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction
- Publication Type:Journal Article
- Keywords:
heart failure;
preserved ejection fraction;
diagnosis;
treatment;
consensus
- From:
Chinese Circulation Journal
2025;40(11):1041-1060
- CountryChina
- Language:Chinese
-
Abstract:
Heart failure with preserved ejection fraction(HFpEF)accounts for nearly 50%of all heart failure patients.To enhance the understanding and awareness of HFpEF and standardize its diagnosis and treatment,the Heart Failure Core Group of the Cardiovascular Physicians Branch of the Chinese Medical Doctor Association and the Expert Committee of the Heart Failure Center organized experts in 2023 and developed China's first evidence-based expert consensus on HFpEF,basing on domestic and international research findings,relevant guidelines,and China's clinical practice.The consensus covers HFpEF phenotyping,diagnostic and therapeutic algorithms,screening for underlying causes and comorbidities,and rehabilitation management.The publication of this consensus has played an effective role in guiding and standardizing the clinical diagnosis and treatment of HFpEF in China.Over the last two years,significant new advances emerged in the field of HFpEF.Consequently,collaborating with the Expert Committee of the Heart Failure Center,the consensus working group has updated and revised the document under the leadership of the Electrocardiogram and Cardiac Function Branch of Chinese Geriatrics Society and the Working Committee of the Heart Failure Comprehensive Management Center of the Chronic Disease Center of the Chinese Center for Disease Control and Prevention.Key issues updated now include the addition of epidemiological data on HFpEF in China,optimization of diagnostic and therapeutic algorithms,and the latest progress and recommendations regarding novel therapeutic drugs since 2023.It is hoped that this updated consensus will provide further guidance and reference for the standardized management of HFpEF in China.
